Adaptin Bio, Inc.
OOTC:APTN6.27
USD
0.00
(0.00%)
CIK
1938571
ISIN
US00654M1009
CUSIP
00654M100
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Michael J. Roberts
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Charlotte United States
- CIK
- 0001938571
- Website
- adaptinbio.com
- Similar Companies
- Business
- Adaptin Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of brain-penetrant precision immunotherapies for the treatment of malignant central nervous system (CNS) tumors and intractable cancers. The company utilizes its proprietary Brain Bispecific T cell Engager (BRiTE) platform, an immune-cell hitchhiking drug delivery technology designed to bypass the blood-brain barrier and transport therapeutic biologics directly into intracerebral tumor microenvironments. The company's core product pipeline and platform assets comprise: APTN-101, a clinical-stage, epidermal growth factor receptor variant III (EGFRvIII)-targeted bispecific T-cell engager engineered to treat World Health Organization (WHO) Grade IV malignant glioma and glioblastoma multiforme (GBM) by redirecting host cytotoxic T lymphocytes to destroy tumor cells; the BRiTE platform, a modular biologic engineering system developed to deliver bispecific antibodies and immunotherapeutic agents across the central nervous system; and preclinical discovery programs focused on expanding bispecific T-cell engager modalities to additional solid tumor and neuro-oncology targets. Headquartered in Charlotte, North Carolina, Adaptin Bio, Inc. was originally founded in 2021 as Centaur Bio Inc. and operates primarily within the United States. In recent corporate developments, the company completed a reverse merger in February 2025 with a subsidiary of Unite Acquisition 1 Corp., pursuant to which its operational activities were structured under Adaptin Bio Operating Corporation and the parent company assumed the name Adaptin Bio, Inc. The transaction was accompanied by approximately $7.7 million in private placement financing to fund clinical operations. In May 2026, the company commenced public trading of its common stock on the OTCQB Venture Market under the ticker symbol APTN. Furthermore, in August 2026, the company initiated patient enrollment in a first-in-human Phase 1 clinical trial evaluating APTN-101, both as a monotherapy and in combination with activated polyclonal T cells, in collaboration with the Preston Robert Tisch Brain Tumor Center at Duke University.